$PCVX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Vaxcyte, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Vaxcyte, Inc.. Get notifications about new insider transactions in Vaxcyte, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 23 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | M | 1.79 | 2,793 | 4,999 | 88,836 | |
Apr 23 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Buy | M | 1.79 | 2,793 | 4,999 | 4,201 | 1.4 K to 4.2 K (+198.37 %) |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 2.03 | 7,611 | 15,450 | 22,027 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 2.03 | 7,611 | 15,450 | 22,027 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 2.03 | 21,871 | 44,398 | 48,197 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 2.03 | 21,871 | 44,398 | 48,197 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 1.79 | 14,253 | 25,513 | 7,173 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 1.79 | 14,253 | 25,513 | 7,173 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 0.80 | 4,168 | 3,334 | 4,168 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | J | 0.80 | 4,168 | 3,334 | 4,168 | |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | J | 0.00 | 38,308 | 0 | 39,591 | 77.9 K to 39.6 K (-49.18 %) |
Apr 07 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | J | 0.00 | 38,308 | 0 | 39,591 | 77.9 K to 39.6 K (-49.18 %) |
Apr 06 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | A | 20.93 | 40,000 | 837,200 | 40,000 | |
Apr 06 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Option Exercise | A | 20.93 | 93,340 | 1,953,606 | 93,340 | |
Apr 06 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | A | 20.93 | 40,000 | 837,200 | 40,000 | |
Apr 06 2021 | PCVX | Vaxcyte, Inc. | Wassil Jim | Chief Operating Off ... | Option Exercise | A | 20.93 | 93,340 | 1,953,606 | 93,340 | |
Apr 06 2021 | PCVX | Vaxcyte, Inc. | GUGGENHIME ANDREW | President and CFO | Option Exercise | A | 20.93 | 145,000 | 3,034,850 | 145,000 | |
Apr 06 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | Chief Executive Off ... | Option Exercise | A | 20.93 | 310,000 | 6,488,300 | 310,000 | |
Mar 29 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | M | 0.04 | 4,750 | 190 | 7,259 | |
Mar 29 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 24.48 | 1,361 | 33,317 | 1,408 | 2.8 K to 1.4 K (-49.15 %) |
Mar 29 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 23.64 | 3,389 | 80,116 | 2,769 | 6.2 K to 2.8 K (-55.03 %) |
Mar 29 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Buy | M | 0.04 | 4,750 | 190 | 6,158 | 1.4 K to 6.2 K (+337.36 %) |
Mar 23 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Option Exercise | M | 1.79 | 15,000 | 26,850 | 448,815 | |
Mar 23 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Sell | S | 25.77 | 15,000 | 386,550 | 578,691 | 593.7 K to 578.7 K (-2.53 %) |
Mar 23 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Buy | M | 1.79 | 15,000 | 26,850 | 593,691 | 578.7 K to 593.7 K (+2.59 %) |
Mar 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Option Exercise | M | 2.03 | 2,500 | 5,075 | 199,968 | |
Mar 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Sell | S | 27.49 | 1,487 | 40,878 | 1,562 | 3 K to 1.6 K (-48.77 %) |
Mar 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Sell | S | 27.01 | 1,013 | 27,361 | 3,049 | 4.1 K to 3 K (-24.94 %) |
Mar 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Buy | M | 2.03 | 2,500 | 5,075 | 4,062 | 1.6 K to 4.1 K (+160.05 %) |
Mar 15 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | M | 1.79 | 2,500 | 4,475 | 21,426 | |
Mar 15 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | S | 25.00 | 2,500 | 62,500 | 77,899 | 80.4 K to 77.9 K (-3.11 %) |
Mar 15 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Buy | M | 1.79 | 2,500 | 4,475 | 80,399 | 77.9 K to 80.4 K (+3.21 %) |
Mar 02 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | M | 0.04 | 4,750 | 190 | 12,009 | |
Mar 02 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 25.33 | 68 | 1,722 | 1,408 | 1.5 K to 1.4 K (-4.61 %) |
Mar 02 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 24.34 | 1,372 | 33,394 | 1,476 | 2.8 K to 1.5 K (-48.17 %) |
Mar 02 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 23.73 | 3,310 | 78,546 | 2,848 | 6.2 K to 2.8 K (-53.75 %) |
Mar 02 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Buy | M | 0.04 | 4,750 | 190 | 6,158 | 1.4 K to 6.2 K (+337.36 %) |
Feb 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Option Exercise | M | 2.03 | 2,500 | 5,075 | 202,468 | |
Feb 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Sell | S | 26.95 | 2,500 | 67,375 | 1,562 | 4.1 K to 1.6 K (-61.55 %) |
Feb 17 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Buy | M | 2.03 | 2,500 | 5,075 | 4,062 | 1.6 K to 4.1 K (+160.05 %) |
Feb 16 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | M | 1.79 | 2,500 | 4,475 | 23,926 | |
Feb 16 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | S | 27.27 | 316 | 8,617 | 77,899 | 78.2 K to 77.9 K (-0.40 %) |
Feb 16 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | S | 26.56 | 2,184 | 58,007 | 78,215 | 80.4 K to 78.2 K (-2.72 %) |
Feb 16 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Buy | M | 1.79 | 2,500 | 4,475 | 80,399 | 77.9 K to 80.4 K (+3.21 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 28.66 | 6,632 | 190,073 | 1,405,418 | 1.4 M to 1.4 M (-0.47 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 27.64 | 7,567 | 209,152 | 1,412,050 | 1.4 M to 1.4 M (-0.53 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.78 | 26,688 | 714,705 | 1,419,617 | 1.4 M to 1.4 M (-1.85 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.75 | 37,271 | 959,728 | 1,446,305 | 1.5 M to 1.4 M (-2.51 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 28.75 | 93,740 | 2,695,025 | 1,483,576 | 1.6 M to 1.5 M (-5.94 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 28.07 | 88,756 | 2,491,381 | 1,577,316 | 1.7 M to 1.6 M (-5.33 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 27.12 | 38,248 | 1,037,286 | 1,666,072 | 1.7 M to 1.7 M (-2.24 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.06 | 28,922 | 753,707 | 1,704,320 | 1.7 M to 1.7 M (-1.67 %) |
Feb 10 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.64 | 50,874 | 1,304,409 | 1,733,242 | 1.8 M to 1.7 M (-2.85 %) |
Feb 04 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.06 | 2,768 | 69,366 | 1,784,116 | 1.8 M to 1.8 M (-0.15 %) |
Feb 04 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.13 | 14,234 | 357,700 | 1,786,884 | 1.8 M to 1.8 M (-0.79 %) |
Feb 02 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.07 | 2,000 | 50,140 | 1,801,118 | 1.8 M to 1.8 M (-0.11 %) |
Jan 28 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | M | 0.04 | 4,750 | 190 | 16,759 | |
Jan 28 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 25.94 | 425 | 11,025 | 1,408 | 1.8 K to 1.4 K (-23.19 %) |
Jan 28 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Sell | S | 25.20 | 4,325 | 108,990 | 1,833 | 6.2 K to 1.8 K (-70.23 %) |
Jan 28 2021 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Buy | M | 0.04 | 4,750 | 190 | 6,158 | 1.4 K to 6.2 K (+337.36 %) |
Jan 27 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.30 | 2,140 | 54,142 | 1,803,118 | 1.8 M to 1.8 M (-0.12 %) |
Jan 27 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.13 | 1,373 | 35,876 | 1,805,258 | 1.8 M to 1.8 M (-0.08 %) |
Jan 27 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.23 | 16,769 | 423,082 | 1,806,631 | 1.8 M to 1.8 M (-0.92 %) |
Jan 27 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.07 | 15,461 | 403,068 | 1,823,400 | 1.8 M to 1.8 M (-0.84 %) |
Jan 27 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.61 | 19,511 | 499,677 | 1,838,861 | 1.9 M to 1.8 M (-1.05 %) |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | Wassil Jim | Chief Operating Off ... | Option Exercise | M | 2.42 | 3,000 | 7,260 | 248,926 | |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | Wassil Jim | Chief Operating Off ... | Sell | S | 25.50 | 3,000 | 76,500 | 16,381 | 19.4 K to 16.4 K (-15.48 %) |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | Wassil Jim | Chief Operating Off ... | Buy | M | 2.42 | 3,000 | 7,260 | 19,381 | 16.4 K to 19.4 K (+18.31 %) |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Option Exercise | M | 1.79 | 15,000 | 26,850 | 478,815 | |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Sell | S | 25.87 | 1,567 | 40,538 | 578,691 | 580.3 K to 578.7 K (-0.27 %) |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Sell | S | 25.01 | 13,433 | 335,959 | 580,258 | 593.7 K to 580.3 K (-2.26 %) |
Jan 21 2021 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Buy | M | 1.79 | 15,000 | 26,850 | 593,691 | 578.7 K to 593.7 K (+2.59 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.05 | 7,000 | 182,350 | 1,888,901 | 1.9 M to 1.9 M (-0.37 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.55 | 42,516 | 1,086,284 | 1,895,901 | 1.9 M to 1.9 M (-2.19 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.05 | 3,808 | 99,198 | 1,938,417 | 1.9 M to 1.9 M (-0.20 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.74 | 22,869 | 588,648 | 1,942,225 | 2 M to 1.9 M (-1.16 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.88 | 14,918 | 386,078 | 1,965,094 | 2 M to 2 M (-0.75 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Option Exercise | M | 2.03 | 2,500 | 5,075 | 204,968 | |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Sell | S | 26.00 | 2,500 | 65,000 | 1,562 | 4.1 K to 1.6 K (-61.55 %) |
Jan 19 2021 | PCVX | Vaxcyte, Inc. | Wright-Mitchell Jane | General Counsel | Buy | M | 2.03 | 2,500 | 5,075 | 4,062 | 1.6 K to 4.1 K (+160.05 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.34 | 3,100 | 81,654 | 1,980,012 | 2 M to 2 M (-0.16 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.90 | 26,010 | 673,659 | 1,983,112 | 2 M to 2 M (-1.29 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 27.05 | 901 | 24,372 | 2,009,122 | 2 M to 2 M (-0.04 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.35 | 17,666 | 465,499 | 2,010,023 | 2 M to 2 M (-0.87 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 27.02 | 12,206 | 329,806 | 2,027,689 | 2 M to 2 M (-0.60 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.69 | 24,980 | 666,716 | 2,039,895 | 2.1 M to 2 M (-1.21 %) |
Jan 13 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 25.42 | 12,480 | 317,242 | 2,064,875 | 2.1 M to 2.1 M (-0.60 %) |
Jan 12 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Option Exercise | M | 1.79 | 2,500 | 4,475 | 26,426 | |
Jan 12 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | S | 26.74 | 1,527 | 40,832 | 77,899 | 79.4 K to 77.9 K (-1.92 %) |
Jan 12 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Sell | S | 25.38 | 973 | 24,695 | 79,426 | 80.4 K to 79.4 K (-1.21 %) |
Jan 12 2021 | PCVX | Vaxcyte, Inc. | Sauer Paul | SVP Process Dev, Ma ... | Buy | M | 1.79 | 2,500 | 4,475 | 80,399 | 77.9 K to 80.4 K (+3.21 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 28.23 | 200 | 5,646 | 2,077,355 | 2.1 M to 2.1 M (-0.01 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 27.08 | 8,944 | 242,204 | 2,077,555 | 2.1 M to 2.1 M (-0.43 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 26.43 | 31,468 | 831,699 | 2,086,499 | 2.1 M to 2.1 M (-1.49 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 29.51 | 469 | 13,840 | 2,117,967 | 2.1 M to 2.1 M (-0.02 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 28.80 | 22,587 | 650,506 | 2,118,436 | 2.1 M to 2.1 M (-1.05 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 27.75 | 24,524 | 680,541 | 2,141,023 | 2.2 M to 2.1 M (-1.13 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 29.99 | 22,507 | 674,985 | 2,165,547 | 2.2 M to 2.2 M (-1.03 %) |
Jan 08 2021 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Sell | S | 29.24 | 34,913 | 1,020,856 | 2,188,054 | 2.2 M to 2.2 M (-1.57 %) |
Dec 30 2020 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | M | 1.79 | 740 | 1,325 | 91,629 | |
Dec 30 2020 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Buy | M | 1.79 | 740 | 1,325 | 1,408 | 668 to 1.4 K (+110.78 %) |
Dec 30 2020 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Option Exercise | M | 1.79 | 740 | 1,325 | 91,629 | |
Dec 30 2020 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | Buy | M | 1.79 | 740 | 1,325 | 1,408 | 668 to 1.4 K (+110.78 %) |
Dec 29 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Option Exercise | M | 1.79 | 5,500 | 9,845 | 493,815 | |
Dec 29 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Buy | M | 1.79 | 5,500 | 9,845 | 578,691 | 573.2 K to 578.7 K (+0.96 %) |
Dec 22 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Option Exercise | M | 1.79 | 15,000 | 26,850 | 499,315 | |
Dec 22 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Sell | S | 29.88 | 2,113 | 63,136 | 573,191 | 575.3 K to 573.2 K (-0.37 %) |
Dec 22 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Sell | S | 29.08 | 5,691 | 165,494 | 575,304 | 581 K to 575.3 K (-0.98 %) |
Dec 22 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Sell | S | 28.42 | 7,196 | 204,510 | 580,995 | 588.2 K to 581 K (-1.22 %) |
Dec 22 2020 | PCVX | Vaxcyte, Inc. | PICKERING GRANT | President & CEO | Buy | M | 1.79 | 15,000 | 26,850 | 588,191 | 573.2 K to 588.2 K (+2.62 %) |
Dec 17 2020 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advis ... | Sell | S | 32.46 | 75,703 | 2,457,456 | 5,074,574 | 5.2 M to 5.1 M (-1.47 %) | |
Dec 17 2020 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advis ... | Sell | S | 33.02 | 6,276 | 207,235 | 5,150,277 | 5.2 M to 5.2 M (-0.12 %) | |
Dec 10 2020 | PCVX | Vaxcyte, Inc. | NEWELL WILLIAM J | Director | Grant | A | 1.29 | 22,228 | 28,674 | 66,684 | 44.5 K to 66.7 K (+50.00 %) |
Oct 09 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 50.69 | 167,661 | 8,498,065 | 5,001,593 | 5.2 M to 5 M (-3.24 %) |
Oct 09 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 50.95 | 98,597 | 5,023,527 | 5,169,254 | 5.3 M to 5.2 M (-1.87 %) |
Oct 01 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 48.64 | 15,967 | 776,705 | 0 | 16 K to 0 (-100.00 %) |
Oct 01 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 50.27 | 124,656 | 6,265,871 | 5,283,818 | 5.4 M to 5.3 M (-2.30 %) |
Oct 01 2020 | PCVX | Vaxcyte, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Sell | S | 52.08 | 80,707 | 4,202,987 | 5,408,474 | 5.5 M to 5.4 M (-1.47 %) |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advis ... | 10% Owner | Option Exercise | C | 0.00 | 747,295 | 0 | 0 | |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advis ... | 10% Owner | Option Exercise | C | 0.00 | 3,471,758 | 0 | 0 | |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advis ... | 10% Owner | Buy | P | 16.00 | 937,500 | 15,000,000 | 5,156,553 | 4.2 M to 5.2 M (+22.22 %) |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | TPG Group Holdings (SBS) Advis ... | 10% Owner | Buy | C | 0.00 | 4,219,053 | 0 | 4,219,053 | 0 to 4.2 M |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Option Exercise | C | 0.00 | 298,917 | 0 | 0 | |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Option Exercise | C | 0.00 | 454,812 | 0 | 0 | |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Option Exercise | C | 0.00 | 1,217,074 | 0 | 0 | |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Option Exercise | C | 0.00 | 2,185,415 | 0 | 0 | |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Buy | P | 16.00 | 12,500 | 200,000 | 4,168,718 | 4.2 M to 4.2 M (+0.30 %) |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Buy | C | 0.00 | 298,917 | 0 | 4,156,218 | 3.9 M to 4.2 M (+7.75 %) |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Buy | C | 0.00 | 454,812 | 0 | 3,857,301 | 3.4 M to 3.9 M (+13.37 %) |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Buy | C | 0.00 | 1,217,074 | 0 | 3,402,489 | 2.2 M to 3.4 M (+55.69 %) |
Jun 18 2020 | PCVX | Vaxcyte, Inc. | EMSTER KURT VON | Director | Buy | C | 0.00 | 2,185,415 | 0 | 2,185,415 | 0 to 2.2 M |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Option Exercise | C | 0.00 | 211,237 | 0 | 0 | |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Option Exercise | C | 0.00 | 226,236 | 0 | 0 | |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Option Exercise | C | 0.00 | 1,692,494 | 0 | 0 | |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Buy | P | 16.00 | 93,000 | 1,488,000 | 2,222,967 | 2.1 M to 2.2 M (+4.37 %) |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Buy | C | 0.00 | 211,237 | 0 | 2,129,967 | 1.9 M to 2.1 M (+11.01 %) |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Buy | C | 0.00 | 226,236 | 0 | 1,918,730 | 1.7 M to 1.9 M (+13.37 %) |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Buy | C | 0.00 | 1,692,494 | 0 | 1,692,494 | 0 to 1.7 M |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Option Exercise | C | 0.00 | 140,824 | 0 | 0 | |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Option Exercise | C | 0.00 | 226,236 | 0 | 0 | |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Option Exercise | C | 0.00 | 1,692,494 | 0 | 0 | |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Buy | P | 16.00 | 250,000 | 4,000,000 | 2,309,554 | 2.1 M to 2.3 M (+12.14 %) |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Buy | C | 0.00 | 140,824 | 0 | 2,059,554 | 1.9 M to 2.1 M (+7.34 %) |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Buy | C | 0.00 | 226,236 | 0 | 1,918,730 | 1.7 M to 1.9 M (+13.37 %) |
Jun 16 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Buy | C | 0.00 | 1,692,494 | 0 | 1,692,494 | 0 to 1.7 M |
Jun 15 2020 | PCVX | Vaxcyte, Inc. | NEWELL WILLIAM J | Director | Option Exercise | A | 16.00 | 40,000 | 640,000 | 40,000 | |
Jun 15 2020 | PCVX | Vaxcyte, Inc. | Lukatch Heath | Director | Option Exercise | A | 16.00 | 40,000 | 640,000 | 40,000 | |
Jun 15 2020 | PCVX | Vaxcyte, Inc. | Hopfner Robert Lorne | Director | Option Exercise | A | 16.00 | 40,000 | 640,000 | 40,000 | |
Jun 15 2020 | PCVX | Vaxcyte, Inc. | Heron Patrick J | Director | Option Exercise | A | 16.00 | 40,000 | 640,000 | 40,000 | |
Jun 15 2020 | PCVX | Vaxcyte, Inc. | Abingworth LLP | 10% Owner | Option Exercise | A | 16.00 | 40,000 | 640,000 | 40,000 |